Teiko.bio Launches with $11.6 Million Series A Financing to Advance High-Dimension Immune Profiling for Clinical Trials and Diagnostics Development

December 20, 2021

Proceeds will fund strategic academic and biopharma partnerships, including a multi-phase discovery program with the Parker Institute for Cancer Immunotherapy to accelerate next-generation I/O drug and diagnostics discovery.

Teiko Bio, a precision immune monitoring company, is excited to announce our raise of $11.6M million in an oversubscribed Series A financing. Our financing is led by HOF Capital with participation from Founders Fund Pathfinder and Global Founders Capital, in addition to funds managed by EPIC Ventures, and other undisclosed angel investors.

Proceeds from our financing will be used to build Teiko’s immune profiling platform and algorithms, with enhanced capabilities to generate predictive immune signatures of patient treatment outcomes and development of interactive client reports. In addition, the funding will also be used to identify and validate predictive signatures and diagnostics through strategic collaborations with world-class cancer centers, including ongoing work with Dr. Siwen Hu-Lieskovan, MD, PhD, Assistant Professor of Medicine and Director of Solid Tumor Immunotherapy at the Huntsman Cancer Institute, University of Utah.

Alongside our launch, we’re also proud to announce a multi-phase discovery partnership with the Parker Institute for Cancer Immunotherapy (PICI), a San Francisco-based nonprofit that enables unprecedented collaboration between the country’s leading immunotherapy researchers and cancer centers, and PICI investigators. The partnership will advance the development of next-generation I/O therapies and diagnostics for solid tumors.

We’re also thrilled to announce the appointment and support of Dr. Chaoyuan (Charlie) Kuang, MD, PhD, Medical Oncologist and Assistant Professor at Albert Einstein College of Medicine, Rick Lanman, MD, former Global CMO of Guardant Health, and Daniel Simon, SVP of BioPharma BD at Guardant Health, to our Scientific and Commercial Advisory Board. Their additions provide experience and expertise in cancer immunotherapy, clinical trials, and diagnostics commercialization.

“We are energized to work alongside a talented group of scientists and inventors to make immune monitoring a clinical reality. We are grateful to have our investors’ support for our mission.” –Matt Spitzer, scientific cofounder and UCSF Assistant Professor, and Ramji Srinivasan, CEO and cofounder.

View the original announcement on LinkedIn here »